Terms: = Uterine cancer AND BCL2, Bcl-2, 596, ENSG00000171791 AND Staging
13 results:
1. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
2. [bcl-2 associated athanogene 3 affects the epithelial-mesenchymal transition in human cervical cancer].
Wei L; Qin XP; Zhao XX; Wang W
Zhonghua Fu Chan Ke Za Zhi; 2017 Aug; 52(8):551-557. PubMed ID: 28851173
[No Abstract] [Full Text] [Related]
3. [A Case of a Metastatic Liver Tumor from a Thymic Carcinoma Detected During a Cesarean Section].
Morinaka T; Takeuchi D; Noro A; Saotome T; Yoshimura K; Kaneko T; Miura S; Kamiya J; Ashizawa Y; Akikusa B; Ogata A
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1824-6. PubMed ID: 26805185
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors.
Stănescu AD; Nistor E; Sajin M; Stepan AE
Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395
[TBL] [Abstract] [Full Text] [Related]
5. bcl-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry.
Porichi O; Nikolaidou ME; Apostolaki A; Tserkezoglou A; Arnogiannaki N; Kassanos D; Margaritis L; Panotopoulou E
Anticancer Res; 2009 Oct; 29(10):3977-82. PubMed ID: 19846939
[TBL] [Abstract] [Full Text] [Related]
6. Expression of p53, bcl-2 and Ki-67 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix.
Looi ML; Dali AZ; Ali SA; Ngah WZ; Yusof YA
Anal Quant Cytol Histol; 2008 Apr; 30(2):63-70. PubMed ID: 18561741
[TBL] [Abstract] [Full Text] [Related]
7. P53 and bcl-2 as prognostic markers in endometrial carcinoma.
Appel ML; Edelweiss MI; Fleck J; Rivero LF; Rivoire WA; Mônego HI; Dos Reis R
Pathol Oncol Res; 2008 Mar; 14(1):23-30. PubMed ID: 18398703
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes.
Kalogiannidis I; Bobos M; Papanikolaou A; Makedos A; Amplianitis I; Vergote I; Nenopoulou E; Makedos G
Eur J Gynaecol Oncol; 2008; 29(1):19-25. PubMed ID: 18386458
[TBL] [Abstract] [Full Text] [Related]
9. Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study.
Tozzi R; Malur S; Koehler C; Schneider A
J Minim Invasive Gynecol; 2005; 12(2):130-6. PubMed ID: 15904616
[TBL] [Abstract] [Full Text] [Related]
10. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer.
Fanning J; Brown S; Phibbs G; Kramer T; Zaher A
Int J Gynecol Cancer; 2002; 12(3):286-9. PubMed ID: 12060450
[TBL] [Abstract] [Full Text] [Related]
11. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract] [Full Text] [Related]
12. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma.
Bell JG; Minnick A; Reid GC; Judis J; Brownell M
Gynecol Oncol; 1997 Sep; 66(3):388-92. PubMed ID: 9299250
[TBL] [Abstract] [Full Text] [Related]
13. Immunohistochemical detection of bcl-2 protein in small cell carcinomas.
Yan JJ; Chen FF; Tsai YC; Jin YT
Oncology; 1996; 53(1):6-11. PubMed ID: 8570134
[TBL] [Abstract] [Full Text] [Related]
